Suppr超能文献

听神经瘤面神经保留术25年进展

A 25-Year Update on the Facial Nerve Sparing Approach for Vestibular Schwannoma.

作者信息

Sisti Jonathan A, Delgardo Mychael W, Yoh Nina, Okolo Ogoegbunam B, Upadhyayula Pavan S, Pascual-Leone Andrés, Paccione Catherine R, Wang Tony J C, Sisti Michael B

机构信息

Department of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA.

Department of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA; Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA.

出版信息

World Neurosurg. 2025 Mar;195:123603. doi: 10.1016/j.wneu.2024.123603. Epub 2025 Jan 30.

Abstract

BACKGROUND

This study updates the results of a facial nerve preservation approach to treating vestibular schwannomas at a single institution by a single surgeon using retrosigmoid craniectomy with microsurgery (MS) and gamma knife stereotactic radiosurgery (SRS) over a 25-year interval.

METHODS

We retrospectively reviewed 751 patients between 1998 and 2023 and grouped them by intervention: MS only (Group 1, 217 patients), SRS only (Group 2, 447 patients), MS then SRS (Group 3, 72 patients), SRS then MS (Group 4, 10 patients), and SRS then SRS (Group 5, 5 patients). The primary outcome variable was facial nerve function, defined as House-Brackmann grade ≤2 at last follow-up.

RESULTS

Good outcomes by group were achieved in 98.2%, 99.6%, 93.1%, 90%, and 100% of patients, respectively. Upfront SRS (Group 2) resulted in significantly better facial nerve outcomes than upfront MS (Groups 1 and 3, 289 patients) (96.9% and 99.4%, P < 0.05). Mean tumor maximum linear diameters were 3.2, 1.32, 3.23, 1.98, and 1.64 cm. Subtotal resection rates in Groups 1, 3, and 4, were 68.2%, 81.9%, and 80%, respectively. The median (interquartile range) follow-up time among patients (minimum follow-up of 12 months) was 52 (26.75-88) months, with a maximum of 297 months (24.75 years). Overall, 98.1% of patients had a good facial nerve outcome with no operative mortality.

CONCLUSIONS

For larger tumors, MS emphasizing facial nerve preservation over gross total resection followed by adjuvant SRS for any interval tumor regrowth yields excellent facial nerve outcomes and tumor control rates. For smaller tumors, upfront SRS achieves superior facial nerve preservation with MS and SRS both viable salvage options for treatment of tumor progression. This paradigm balances tumor control, facial nerve preservation, and low morbidity.

摘要

背景

本研究更新了一位外科医生在单一机构采用乙状窦后开颅显微手术(MS)和伽玛刀立体定向放射外科手术(SRS),在25年期间对面神经保留方法治疗前庭神经鞘瘤的结果。

方法

我们回顾性分析了1998年至2023年间的751例患者,并根据干预措施将他们分组:单纯MS(第1组,217例患者)、单纯SRS(第2组,447例患者)、MS后SRS(第3组,72例患者)、SRS后MS(第4组,10例患者)以及SRS后SRS(第5组,5例患者)。主要结局变量为面神经功能,定义为最后一次随访时House-Brackmann分级≤2级。

结果

各组分别有98.2%、99.6%、93.1%、90%和100%的患者取得了良好结局。 upfront SRS(第2组)导致的面神经结局明显优于 upfront MS(第1组和第3组,共289例患者)(分别为96.9%和99.4%,P < 0.05)。肿瘤最大线性直径的平均值分别为3.2、1.32、3.23、1.98和1.64厘米。第1组、第3组和第4组的次全切除率分别为68.2%、81.9%和80%。患者的中位(四分位间距)随访时间(最短随访12个月)为52(26.75 - 88)个月,最长为297个月(24.75年)。总体而言,98.1%的患者面神经结局良好,且无手术死亡。

结论

对于较大的肿瘤,在强调保留面神经而非全切肿瘤的MS之后,对于任何间隔期的肿瘤复发采用辅助SRS,可获得出色的面神经结局和肿瘤控制率。对于较小的肿瘤, upfront SRS能实现更优的面神经保留,而MS和SRS都是治疗肿瘤进展可行的挽救选择。这种模式平衡了肿瘤控制、面神经保留和低发病率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验